TH287 10mg 10mg | Purity Not Available
Adooq Bioscience
TH287 is a potent inhibitor of MTH1 (NUDT1) with an IC50 value of 0.8 nM, less potent for MTH2, NUDT5, NUDT12, NUDT14, and NUDT16,
More Information Supplier PageSearch Results
SR9243 50mg 50mg | Purity Not Available
Adooq Bioscience
SR9243 is a potent and selective LXR inverse agonist. SR9243 kills cancer cells by inhibiting lipid production and the Warburg effect. It induces cell death in multiple types of cancer and does not cause the side effects that have derailed previous attempts to target these processes.
More Information Supplier PageSR9243 25mg 25mg | Purity Not Available
Adooq Bioscience
SR9243 is a potent and selective LXR inverse agonist. SR9243 kills cancer cells by inhibiting lipid production and the Warburg effect. It induces cell death in multiple types of cancer and does not cause the side effects that have derailed previous attempts to target these processes.
More Information Supplier PageSR9243 10mg 10mg | Purity Not Available
Adooq Bioscience
SR9243 is a potent and selective LXR inverse agonist. SR9243 kills cancer cells by inhibiting lipid production and the Warburg effect. It induces cell death in multiple types of cancer and does not cause the side effects that have derailed previous attempts to target these processes.
More Information Supplier PageBLU9931 5mg 5mg | Purity Not Available
Adooq Bioscience
BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM),
More Information Supplier PageBLU9931 25mg 25mg | Purity Not Available
Adooq Bioscience
BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM),
More Information Supplier PageBLU9931 10mg 10mg | Purity Not Available
Adooq Bioscience
BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM),
More Information Supplier PageTAS-102 5mg 5mg | Purity Not Available
Adooq Bioscience
TAS-102 is an orally bioavailable combination agent composed of the cytotoxic pyrimidine analog Trifluridine (5-trifluoro-2??-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. TAS102= Trifluridine and tipiracil HCl (molar ratio = 1.0 : 0.5 or 2:1)
More Information Supplier PageTAS-102 2mg 2mg | Purity Not Available
Adooq Bioscience
TAS-102 is an orally bioavailable combination agent composed of the cytotoxic pyrimidine analog Trifluridine (5-trifluoro-2??-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. TAS102= Trifluridine and tipiracil HCl (molar ratio = 1.0 : 0.5 or 2:1)
More Information Supplier PagePRT-060318 25mg 25mg | Purity Not Available
Adooq Bioscience
PRT-060318 is a novel selective inhibitor of the tyrosine kinase Syk, as an approach to HIT treatment.
More Information Supplier Page